Becton Dickinson stock edges lower as conference highlights Alaris headwind and dividend payout

Becton, Dickinson and Company stock (ISIN US0718131099) closed at USD 179.10 on the New York Stock Exchange on September 8, 2026, down about 3.0 percent from the prior close and leaving the shares between their 52-week low of USD 127.62 and high of USD 193.07 as the medtech group navigates portfolio changes and an upcoming dividend payout.

Conference spotlights portfolio shift and Alaris headwind

At the Wells Fargo 21st Annual Healthcare Conference held on September 9, 2026, Becton, Dickinson and Company highlighted that its slimmer portfolio is delivering stronger growth and margins in several core businesses after a series of divestments and separations completed earlier in fiscal 2026, including the spin-off of Embecta, the sale of BD Mueller and the separation of its life sciences business to Waters in February 2026, according to Investing.com.

Management told investors that fiscal third quarter 2026 was the first full period in which BD operated as a more focused company, and that the latest quarter showed broad momentum with 4.4 percent organic revenue growth and roughly 90 percent of its portfolio achieving high-single-digit growth or better, as reported by Investing.com.

For investors, the quantified comparison is key: organic revenue growth of 4.4 percent in fiscal Q3 2026 sits in the mid-single-digit range that BD targets over time and contrasts with low-single-digit guidance for fiscal 2027, illustrating how temporary headwinds, rather than structural weakness, are capping next year’s growth, according to Investing.com.

Guidance and capital returns frame the medium-term story

Looking ahead, BD reiterated that fiscal 2026 revenue is expected to grow in the low-single-digit range and said it has raised its full-year guidance toward the upper end of that low-single-digit band, signaling confidence that the 4.4 percent organic growth achieved in fiscal Q3 2026 can be sustained around that level for the full year, based on remarks cited by Investing.com Brasil.

For fiscal 2027, management is more cautious, projecting low-single-digit revenue growth and modest earnings-per-share leverage as a mechanical comparison headwind from the Alaris infusion system weighs on reported numbers; BD quantified this headwind at roughly 200 basis points on revenue growth for fiscal 2027 and mentioned that comparable pressures from Alaris, vaccines and China pricing combined to create about 250 basis points of headwinds in fiscal 2026, according to Investing.com.

BD emphasized that pricing has been positive across fiscal 2026 even after absorbing more than USD 130 million of negative price impact from China’s value-based procurement programs, a figure that highlights both the pressure from that market and the company’s ability to offset it through mix and pricing elsewhere in its global portfolio, as noted by Investing.com.

Capital allocation is another pillar of BD’s narrative: management said around USD 2 billion of proceeds from the Waters transaction have been used for share repurchases in fiscal 2026, underlining a commitment to returning capital to shareholders alongside funding growth investments, according to Investing.com Brasil.

Dividend and analyst consensus add to the investment picture

Alongside the conference narrative, Becton Dickinson stock is also shaped by its dividend profile. The company recently declared a quarterly dividend of USD 1.05 per share with an ex-dividend date of September 9, 2026 and a payment date of September 30, 2026, which annualizes to USD 4.20 per share and represents a dividend yield of about 2.3 percent at recent prices, according to GuruFocus.

Data compiled by MarketBeat show that analysts currently assign Becton Dickinson stock a consensus rating of Hold, with an average target price of USD 187.67, placing the latest closing level of USD 179.10 on September 8, 2026 about USD 8.57, or roughly 4.8 percent, below that consensus target.

For income-focused investors, the combination of a 2.3 percent dividend yield and a share price trading moderately below the consensus target suggests a balance between near-term return of capital and expectations of mid-single-digit long-term growth once the Alaris comparison effect fades after fiscal 2027, an outcome BD’s leadership has said they anticipate as the mechanical headwind rolls off, based on comments summarized by Investing.com.

Stock valuation and trading range

From a valuation perspective, one recent overview from GuruFocus noted that BD shares at USD 179.10 on September 8, 2026 were trading about 2.6 percent below a GF Value estimate of USD 183.88, framing the stock as modestly undervalued relative to that proprietary fair-value metric.

The same analysis pointed out that Becton Dickinson stock has traded in a 52-week range of USD 127.62 to USD 193.07, so the latest closing price is approximately USD 51.48 above the 52-week low and USD 13.97 below the high, a spread that suggests the shares have already recovered substantially from their trough but still sit short of the top of their recent range, according to GuruFocus.

Per price data from a major stock portal, Becton Dickinson stock traded at around USD 179.10 on the New York Stock Exchange on September 8, 2026 with a market capitalization in the tens of billions of dollars and daily volume in the several-hundred-thousand-share range, confirming that the stock remains a large, liquid medtech name that responds quickly to changes in guidance, conference commentary and macro health-care trends.

More news and analyses on Becton, Dickinson and Company stock